| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.7B | ¥3.7B | -54.3% |
| Operating Income | ¥-1.2B | ¥-0.8B | -59.7% |
| Ordinary Income | ¥-1.3B | ¥-0.8B | -56.6% |
| Net Income | ¥-1.4B | ¥-0.8B | -77.6% |
| ROE | -22.8% | -10.6% | - |
FY2026 Q1 results show Revenue of 1.7B yen (YoY -54.3%), Operating Loss of 1.2B yen (loss expanded from prior 0.8B yen, YoY -59.7%), Ordinary Loss of 1.3B yen (loss expanded from prior 0.8B yen, YoY -56.6%), and Net Loss of 1.4B yen (loss expanded from prior 0.8B yen, YoY -77.6%). The quarter was characterized by a severe revenue contraction while SG&A expenses of 1.8B yen exceeded gross profit of 0.5B yen, resulting in a deeply negative operating margin of -72.4%. Basic EPS deteriorated to -10.44 yen from -7.17 yen in the prior year period. Despite maintaining a gross margin of 30.5%, the fixed cost burden overwhelmed profitability, leading to ROE of -22.8% and substantial equity erosion from 7.2B yen to 5.9B yen. The company forecasts full-year Revenue of 13.8B yen (+59.0% YoY) with Operating Income of 0.8B yen and Net Income of 2.3B yen, implying a strong second-half recovery scenario that appears challenging given Q1 progress rates.
Revenue declined 2.0B yen (-54.3% YoY) from 3.7B yen to 1.7B yen, representing a severe demand shock in the quarter. The company operates two reportable segments: Healthcare Solutions and Earth Environment Solutions, plus corporate expenses. Corporate costs of 77.8 million yen not allocated to segments represent primarily general administrative expenses that burden overall profitability. Segment impairment losses totaled 1.1 million yen, with Healthcare Solutions contributing 0.2 million yen and Earth Environment Solutions 0.6 million yen as non-recurring factors. Cost of sales decreased to 1.2B yen, yielding gross profit of 0.5B yen at a 30.5% margin, but SG&A expenses of 1.8B yen resulted in operating loss of 1.2B yen. The SG&A ratio of 103.1% against revenue indicates severe operating leverage issues where fixed costs could not adjust to the revenue decline. Non-operating items contributed a net expense of 0.07B yen, comprising non-operating income of 0.01B yen and non-operating expense of 0.08B yen, leading to ordinary loss of 1.3B yen. Special items included extraordinary income of 0.4B yen and extraordinary loss of 0.04B yen, reducing pre-tax loss to 1.3B yen and net loss to 1.4B yen after taxes. The gap between operating loss and net loss widened due to non-operating expenses and the partial offset from extraordinary gains. This represents a Revenue Down/Profit Down pattern with accelerating loss expansion, driven by revenue contraction outpacing cost reduction capabilities.
Segment-level revenue and operating income details are not fully disclosed in the provided data. The company reports two segments: Healthcare Solutions Business and Earth Environment Solutions Business, with unallocated corporate costs of 77.8 million yen. Impairment disclosures indicate both segments incurred fixed asset impairments totaling 1.1 million yen, with Earth Environment Solutions bearing the larger portion at 0.6 million yen versus Healthcare Solutions at 0.2 million yen. Without revenue and operating income breakdowns by segment, identifying the core business by scale is not feasible from the available data. The presence of impairments in both segments suggests operational challenges across the portfolio.
[Profitability] ROE of -22.8% reflects severe capital inefficiency driven by net loss against shrinking equity base, substantially deteriorating from already-negative prior period levels. Operating margin of -72.4% represents a 72.4 percentage point deterioration versus typical positive margins, with net profit margin of -79.4% indicating bottom-line losses exceeding operating losses. Gross margin maintained at 30.5% suggests pricing power or product mix preservation despite revenue decline. [Cash Quality] Cash and deposits of 3.9B yen decreased 1.7B yen (-29.9% YoY), covering 0.55 times current liabilities of 7.1B yen, indicating tightening liquidity. Short-term debt coverage capacity is moderate but declining. [Investment Efficiency] Asset turnover of 0.13 times remains well below industry standards, reflecting low revenue generation per yen of assets, constrained by large investment securities holdings of 2.7B yen. Receivables turnover period extended significantly with DSO rising to 180 days from 89 days YoY, and inventory turnover slowed to 198 days from 78 days YoY, indicating working capital deterioration. [Financial Health] Equity ratio of 45.3% declined from 51.9% YoY, remaining above minimum adequacy but trending downward due to accumulated losses. Current ratio of 141.3% and debt-to-equity ratio of 1.21 suggest surface-level balance sheet stability, though cash burn threatens medium-term sustainability.
Cash and deposits decreased 1.7B yen YoY to 3.9B yen, representing a 29.9% decline that signals significant cash consumption during the quarter. The reduction occurred alongside operating losses of 1.2B yen, suggesting operating activities were a primary cash drain. Working capital movements show accounts receivable increased 0.2B yen (+34.4%) to 0.8B yen while inventories rose 0.2B yen (+126.6%) to 0.4B yen, collectively tying up 0.4B yen in working capital expansion. Accounts payable increased 0.4B yen (+209.2%) to 0.6B yen, providing partial cash preservation through extended supplier credit, though this also reflects potential payment stress. The combination of operating losses, working capital absorption, and modest extraordinary income of 0.4B yen resulted in net cash outflow. Cash coverage of current liabilities stands at 0.55 times, down from more comfortable levels, indicating liquidity adequacy is deteriorating but not yet critical given investment securities of 2.7B yen as secondary liquidity buffer.
Ordinary loss of 1.3B yen versus operating loss of 1.2B yen shows non-operating net expense of approximately 0.07B yen, representing minimal variance between operating and ordinary results. Non-operating items include interest and dividend income within the 0.01B yen non-operating income, offset by 0.08B yen non-operating expenses. Extraordinary income of 0.4B yen partially offset operating losses in reaching net loss of 1.4B yen, indicating reported results include non-recurring benefits that mask underlying operational deterioration. Excluding extraordinary items, core quarterly loss would approximate 1.8B yen, substantially worse than reported net loss. The gap between gross profit of 0.5B yen and SG&A expenses of 1.8B yen represents a structural earnings quality issue where variable margins cannot support fixed cost infrastructure. Operating cash flow data is not disclosed for the quarter, preventing assessment of whether reported losses correspond to actual cash consumption, though the 1.7B yen cash decline suggests earnings quality is poor with losses translating to real cash drain.
Progress against full-year guidance shows Q1 Revenue of 1.7B yen represents 12.3% of the 13.8B yen full-year forecast, significantly below the standard 25% quarterly progression. Operating Income shows Q1 loss of 1.2B yen against full-year forecast of 0.8B yen profit, indicating negative 150% progress and requiring substantial second-half turnaround. Ordinary Income Q1 loss of 1.3B yen versus full-year forecast of 0.7B yen profit similarly demands sharp reversal. Net Income Q1 loss of 1.4B yen against full-year forecast of 2.3B yen profit implies the company must generate approximately 3.7B yen net income over the remaining three quarters to meet guidance. The severe Q1 underperformance suggests guidance may require downward revision unless exceptional demand recovery materializes. The 59% full-year revenue growth forecast from prior year appears increasingly optimistic given Q1 contracted 54.3% YoY, requiring subsequent quarters to achieve growth rates exceeding 100% to compensate. No order backlog data is disclosed to provide forward revenue visibility, increasing uncertainty around guidance achievability.
Annual dividend forecast is 0.00 yen with no interim or year-end dividends planned, maintaining the zero-dividend policy from prior periods. Payout ratio is not applicable given the dividend is zero and the company is reporting net losses. No share buyback activities are disclosed for the period. Total shareholder return ratio is zero as neither dividends nor buybacks are being executed. The absence of shareholder returns is consistent with the company's negative profitability and need to preserve cash resources given declining cash balances and operating losses. Dividend resumption would require return to sustained profitability and positive free cash flow generation.
Severe liquidity deterioration risk from cash declining 1.7B yen (-29.9%) to 3.9B yen in Q1 alone, projecting potential cash exhaustion within 12-18 months at current burn rates if operations do not improve and working capital continues expanding. Revenue recovery execution risk as Q1 revenue of 1.7B yen represents only 12.3% of full-year guidance requiring 13.8B yen, implying remaining quarters must average 4.0B yen per quarter (235% above Q1 levels) to meet forecasts, with no disclosed backlog supporting such inflection. Operating leverage risk from fixed cost structure where SG&A of 1.8B yen exceeds gross profit, requiring revenue to at least triple from current levels to reach breakeven, with no disclosed restructuring plans to right-size cost base if revenue recovery fails to materialize.
[Industry Position] (Reference - Proprietary Analysis). Profitability: ROE -22.8% substantially underperforms industry median of 3.6%, placing the company at the bottom of peer distribution and indicating severe capital destruction versus peer value creation. Operating Margin -72.4% compares unfavorably to industry median net profit margin of 7.4%, reflecting structural operational disadvantage. Financial Health: Equity Ratio 45.3% exceeds industry median of 39.7%, suggesting relatively stronger capitalization, though the ratio is declining due to accumulated losses. Efficiency: Asset Turnover 0.13 times trails industry median of 0.21 times, indicating poor asset utilization. Working capital metrics show significant deterioration with Receivables Turnover extending to 180 days versus industry median of 317 days, while Inventory Turnover of 198 days compares to industry median of 197 days, and Payables Turnover of 284 days versus industry median of 287 days. Revenue Growth -54.3% YoY sharply underperforms industry median growth of 3.8%, representing the most severe performance gap. The company's financial leverage of 2.21 times is below industry median of 2.39 times, though this provides minimal benefit given negative returns. Overall, the company ranks below industry standards across all key profitability and efficiency dimensions, with only equity ratio positioning showing relative strength that is being eroded by operating losses. (Industry: Trading sector, N=4 companies, Comparison: Prior fiscal periods, Source: Proprietary analysis)
First, the company faces critical near-term operational challenges requiring immediate revenue recovery and cost restructuring, as evidenced by Q1 revenue representing only 12.3% of full-year guidance and operating losses consuming cash at 1.7B yen per quarter pace, making full-year guidance achievement highly uncertain without demonstrable turnaround in Q2 results. Second, working capital deterioration with DSO extending to 180 days and DIO reaching 198 days represents 378 days of operating cycle, indicating either fundamental business model stress or collection/inventory management breakdowns that directly threaten liquidity given cash declining to 3.9B yen. Third, the structural disconnect between 30.5% gross margin and -72.4% operating margin reveals SG&A expenses of 1.8B yen are misaligned with current revenue scale of 1.7B yen, suggesting the business requires either rapid revenue scale expansion to support existing infrastructure or significant cost structure reduction to match current demand levels.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.